Zedge (AMEX:ZDGE) 주식

Zedge

Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.

5 Stocks To Watch Heading Into Friday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

MITK

RICK

ZDGE

월요일(16일) 미국 주식 선물이 상승하고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식들은 다음과 같다. 월요일 주목해야 할 주식: 젯지, 컴퍼스 미네랄스, 웨스턴 유니온, 미텍 및 RCI 호스피탈리티

월요일 주목해야 할 주식: 젯지, 컴퍼스 미네랄스, 웨스턴 유니온, 미텍 시스템즈 및 RCI 호스피탈리티

Zedge Inc

Dine Brands Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) shares gained <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">on Wednesday</a> after reporting the first-quarter earnings.
The company clocked <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45248092/dine-brands-global-inc-reports-first-quarter-2025-results" rel="noreferrer noopener">first-quarter FY25 revenue growth</a> of 4.1% year-on-year to $214.78 million, missing the analyst consensus estimate of $217.56 million.
The increase was primarily due to an increase in company restaurant sales, which were mainly attributable to the acquisition of 47 Applebee&#8217;s restaurants in the fourth quarter of 2024.
Adjusted EPS of $1.03 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the analyst consensus</a> estimate of $1.23.
Applebee&#8217;s year-over-year domestic comparable same-restaurant sales declined 2.2%&nbsp;while those of IHOP&#8217;s fell 2.7%.
General and Administrative expenses declined 1.7% to $52.2 million. Gross profit decreased 7.3% to $90.3 million with a gross margin of 42%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/restaurants/25/05/45177147/mcdonalds-stumbles-on-weak-traffic-despite-margin-gains-and-analyst-optimism" rel="noreferrer noopener">McDonald&#8217;s Stumbles On Weak Traffic, Despite Margin Gains And Analyst Optimism</a>
Adjusted EBITDA fell 10% to $54.7 million.
Operating cash flow for the quarter totaled $16.1 million, and adjusted free cash flow was $14.6 million. As of March 31, 2025, the company held $186.5 million in cash and equivalents.
&#8220;As we navigate the current operating environment, the fundamentals of our business remain strong, and since the second half of the quarter, we&#8217;re seeing steady improvement across sales, traffic, and our development pipeline,&#8221; said CEO John Peyton.
Outlook FY25: Applebee&#8217;s domestic system-wide comparable same-restaurant sales performance is expected to be negative 2% and positive 1%.
IHOP&#8217;s domestic system-wide comparable same-restaurant sales performance is expected to be negative 1% and positive 2%.
Dine Brands expects adjusted EBITDA of $235 million—$245 million and capital expenditures of $20 million—$30 million.
Price Action: DIN shares closed higher by 2.05% to $20.38 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45237060/despite-nikes-executive-overhaul-ongoing-challenges-persist-says-analyst" target="_blank" rel="noreferrer noopener">Nike Revamps C-Suite, &#8216;Win Now&#8217; Strategy Faces Profit Pressure: Analyst</a></li>
</ul>
Photo by Tada Images via Shutterstock

Guidance

Movers

General

What's Going On With Applebee Parent Dine Brands Stock On Wednesday?

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) raises FY2025 sales outlook from $254.00 million-$265.00 million to $256.00 million-$265.00 million vs $260.00 million estimate.

Viemed Healthcare Raises FY2025 Sales Guidance from $254.00M-$265.00M to $256.00M-$265.00M vs $260.00M Est

Global Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNL#NYSE">GNL</a>) affirms FY2025 FFO guidance from $0.90-$0.96 to $0.90-$0.96 vs $1.00 analyst estimate..

Global Net Lease Affirms FY2025 FFO Guidance of $0.90-$0.96 vs $1.00 Est

Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) affirms FY2025 Adj EPS guidance from $0.41-$0.51 to $0.41-$0.51 vs $0.38 analyst estimate. Affirms FY2025 sales outlook from $1.05 billion-$1.08 billion to $1.05 billion-$1.08 billion vs $1.07 billion estimate.

EHAB

Enhabit Affirms FY2025 Adj EPS Guidance of $0.41-$0.51 vs $0.38 Est; Affirms FY2025 Sales Guidance of $1.05B-$1.08B vs $1.07B Est

Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.14 by 228.57 percent. This is a 611.11 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $78.00 million which beat the analyst consensus estimate of $75.41 million by 3.44 percent. This is a 15.00 percent increase over sales of $67.83 million the same period last year.

Earnings Beats

CRNC

Cerence Q2 EPS $0.46 Beats $0.14 Estimate, Sales $78.00M Beat $75.41M Estimate

Axon Enterprise Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) shares are rising in after-hours Wednesday after the company beat first-quarter estimates and raised its <a href="https://www.benzinga.com/pressreleases/25/05/n45265409/axon-reports-q1-2025-revenue-of-604-million-up-31-year-over-year">full-year guidance</a>.
Q1 Earnings: Axon reported first-quarter revenue of $603.63 million, beating analyst estimates of $583.76 million. The company reported first-quarter adjusted earnings of $1.41 per share, beating analyst estimates of $1.27 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 31% year-over-year. Axon&#8217;s first-quarter results were led by strength in Software and Services, which generated&nbsp;$263 million&nbsp;in revenue, up&nbsp;39%&nbsp;year-over-year.
Axon raised its full-year guidance from a range of $2.55 billion to $2.65 billion to a new range of $2.6 billion to $2.7 billion versus estimates of $2.62 billion.
&#8220;Strong alignment with our customers, expanding vertical applications and sustained product innovation underpin Axon&#8217;s increased&nbsp;outlook&nbsp;for the remainder of the year,&#8221; the company said.
AXON Price Action: <a href="http://benzinga.com/quote/axon">Axon Enterprise shares</a> were up 4.68% at $630 in extended trading at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45269045/applovin-stock-shakes-off-short-seller-report-shares-surge-on-q1-earnings-beat">AppLovin Stock Shakes Off Short Seller Report, Shares Surge On Q1 Earnings Beat</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

After-Hours Center

AXON

Axon Enterprise Stock Pops On Q1 Earnings: Key Details

Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) affirms FY2025 sales outlook from $235.00 million-$255.00 million to $235.00 million-$255.00 million vs $267.50 million estimate.

ISPO

Inspirato Affirms FY2025 Sales Guidance of $235.00M-$255.00M vs $267.50M Est

Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) sees FY2026 sales of $15.208 billion vs $15.14 billion analyst estimate.

Kyndryl Hldgs Sees FY2026 Revenue to be up by 1% YoY

RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) has outperformed the market over the past 15 years by 5.78% on an annualized basis producing an average annual return of 16.87%. Currently, RBC Bearings has a market capitalization of $10.76 billion. 
Buying $1000 In RBC: If an investor had bought $1000 of RBC stock 15 years ago, it would be worth $10,291.73 today based on a price of $342.20 for RBC at the time of writing.
<h3>RBC Bearings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746656111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In RBC Bearings 15 Years Ago Would Be Worth This Much Today

Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) reported quarterly earnings of $0.41 per share. This is a 2.5 percent increase over earnings of $0.40 per share from the same period last year. The company reported $65.45 million in sales this quarter. This is a 14.74 percent increase over sales of $57.04 million the same period last year.

Smartstop Self Storage Q1 FFO $0.41 Up From $0.40 YoY, Sales $65.45M Up From $57.04M YoY

goeasy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GSY#TSX">GSY</a>) affirms FY2025 sales outlook from $1.62 billion-$1.82 billion to $1.62 billion-$1.82 billion.

TSX:GSY

goeasy Affirms FY2025 Sales Guidance of $1.62B-$1.82B

WIIM

BROS

BROS stock has given up its prior gain. Dutch Bros shares were trading higher after the company reported better-than-expected Q1 financial results.

B2Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>) reported quarterly earnings of $0.09 per share which met the analyst consensus estimate. This is a 50 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $532.11 million which missed the analyst consensus estimate of $579.94 million by 8.25 percent. This is a 15.31 percent increase over sales of $461.44 million the same period last year.

Earnings Misses

B2Gold Q1 Adj. EPS $0.09, Inline, Sales $532.11M Miss $579.94M Estimate

MercadoLibre Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) shares are rising in extended trading on Wednesday after the company reported better-than-expected results <a href="https://www.benzinga.com/pressreleases/25/05/g45267551/mercado-libre-builds-on-2024-momentum-with-strong-q1-2025-results-reporting-5-9-billion-revenue-an">for the first quarter</a>.
<ul>
<li>Q1 Revenue: $5.93 billion, versus <a href="http://benzinga.com/quote/meli/estimates">estimates</a> of $5.51 billion</li>
</ul>
<ul>
<li>Q1 EPS: $9.74, versus estimates of $8.03</li>
</ul>
Total revenue increased 37% on a year-over-year basis, boosted by continued strategic investments. Commerce revenue climbed 32% year-over-year, Financial revenue increased 37% and Fintech revenue from Mercado Pago jumped 43%. 
The Latin America e-commerce and fintech platform company said brand preference reached all-time highs in key markets during the quarter, including Brazil, Mexico, Argentina and Chile. 
&#8220;Mercado Libre started 2025 with exceptional momentum, driven by strong operational performance across both commerce and fintech,&#8221; said Martin de los Santos, CFO of MercadoLibre.
&#8220;This quarter highlights our continued commitment to sustainable, profitable growth as we capture the many opportunities ahead. We remain a key force in accelerating the shift from traditional retail to e-commerce, supported by ongoing investments aimed at delivering a seamless user experience.&#8221;
MELI Price Action: <a href="http://benzinga.com/quote/meli">MercadoLibre shares</a> were up 1.48% in Wednesday&#8217;s after-hours session, trading at $2,262.09 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45183831/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-63">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Octavio_Hoyos">Octavio Hoyos</a>/Shutterstock.

Fintech news covering the emerging Financial Technology services sector

Fintech

Global

MELI

MercadoLibre Stock Surges On Q1 Earnings Beat: 'Exceptional Momentum'

Bank Bradesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDO#NYSE">BBDO</a>) reported quarterly earnings of $0.09 per share. This is a 21.43 percent increase over earnings of $0.07 per share from the same period last year. The company reported $3.82 billion in sales this quarter. This is a 4.63 percent increase over sales of $3.65 billion the same period last year.

BBDO

Bank Bradesco Q1 EPS $0.09 Up From $0.07 YoY, Sales $3.82B Up From $3.65B YoY

Pizza Pizza Royalty (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PZA#TSX">PZA</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported $9.73 million in sales this quarter. This is a 1.85 percent increase over sales of $9.55 million the same period last year.

TSX:PZA

Pizza Pizza Royalty Q1 Adj. EPS $0.23, Inline, Sales $9.73M Up From $9.55M YoY

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.54, a high estimate of $4.50, and a low estimate of $1.00. This current average represents a 28.85% decrease from the previous average price target of $3.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655276_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Offerpad Solutions by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$1.00</td>
<td>$2.25</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$2.25</td>
<td>$3.15</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$4.50</td>
<td>$4.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Offerpad Solutions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Offerpad Solutions compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Offerpad Solutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Offerpad Solutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OPAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Offerpad Solutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Offerpad Solutions</h2>
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
<h3>Offerpad Solutions: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Offerpad Solutions's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -27.52% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.94%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Offerpad Solutions's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.84%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Offerpad Solutions's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Offerpad Solutions's debt-to-equity ratio stands notably higher than the industry average, reaching 5.0. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

OPAD

What Analysts Are Saying About Offerpad Solutions Stock

Across the recent three months, 7 analysts have shared their insights on Expeditors International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $113.29, a high estimate of $128.00, and a low estimate of $105.00. Highlighting a 3.85% decrease, the current average has fallen from the previous average price target of $117.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655268_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Expeditors International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Bascome Majors</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$108.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$128.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Expeditors International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Expeditors International compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Expeditors International's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXPD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Expeditors International analyst ratings.</a>
<h2>All You Need to Know About Expeditors International</h2>
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.
<h3>A Deep Dive into Expeditors International's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Expeditors International's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.72%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Expeditors International's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.98% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Expeditors International's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Expeditors International's debt-to-equity ratio is below the industry average. With a ratio of 0.26, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPD

What 7 Analyst Ratings Have To Say About Expeditors International

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) sees Q2 sales of $235.000 million-$243.000 million vs $243.71 million analyst estimate.

BMBL

Bumble Sees Q2 Sales $235.000M-$243.000M vs $243.71M Est

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.36, a high estimate of $29.00, and a low estimate of $7.00. A decline of 17.71% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655260_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Myriad Genetics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Myriad Genetics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Key Indicators: Myriad Genetics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.12% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MYGN

What Analysts Are Saying About Myriad Genetics Stock

Press Releases

Zedge Announces Fourth Quarter and Full Year Fiscal 2024 Results

Zedge Marketplace Introduces Major Website Updates

Emojipedia Launches Free AI-Powered Emoji Creator

Zedge To Report First Fiscal Quarter 2025 Results

Zedge Announces First Quarter Fiscal 2025 Results

Zedge Announces GuruShots Restructuring to Improve Profitability and Position Itself for Long-term Growth

Zedge Increases Cost Reduction Efforts to a Targeted $4 Million Annually

Zedge To Report Second Fiscal Quarter 2025 Results

Zedge Announces Second Quarter Fiscal 2025 Results

Events

Zedge to Present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

Giftify

HWH International

Intelligent Protection Management Corp. - Common Stock

Intelligent Protection

IZEA Worldwide

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings

MoneyHero Limited - Class A Ordinary Shares

MoneyHero

Outbrain

Oriental Culture Holding LTD - Ordinary Shares

Oriental Culture Holding

PSQ Holdings

Super League Enterprise, Inc. - Common Stock

Super League Enterprise

System1

So-Young International Inc. - American Depository Shares

So-Young Intl

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

VS Media Holdings Limited - Class A Ordinary Shares

VS Media Holdings

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

Zedge

뉴스

파트너 / 기고자

벤징가 글로벌